Log in to search using one of your social media accounts:

 

Françoise Barré-Sinoussi: 'Ruling out a cure for Aids would not be French'
The scientist who helped discover the HIV retrovirus talks about her work and why she is convinced a cure for Aids can be foundFor Françoise Barré-Sinoussi, San Francisco holds poignant memories. The Nobel prize-winning virologist based at the Pasteur Institute in Paris is attending a conference on how to rid the world of Aids. But the city reminds her of the terrible early years of the disease. She first met a person dying from Aids in a hospital in San Francisco in 1984. "It was a very moving moment," she recalls. "He told me, 'Thank you' and I didn't understand why. So I asked and he said, '...
Source: Guardian Unlimited Science - February 15, 2014 Category: Science Authors: Zoë Corbyn Tags: Medical research Nobel prizes Society Features Aids and HIV The Observer Science Source Type: news

Long distance signals protect brain from viral infections
(American Society for Microbiology) The brain contains a defense system that prevents at least two unrelated viruses -- and possibly many more -- from invading the brain at large. The research is published online ahead of print in the Journal of Virology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 10, 2014 Category: Infectious Diseases Source Type: news

Effects of TB Treatment on Virologic and CD4 Response to ARTEffects of TB Treatment on Virologic and CD4 Response to ART
Does TB treatment at ART initiation affect virologic and CD4 count response in HIV-infected adults? AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 27, 2014 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Daclatasvir–sofosbuvir combo effective in chronic HCV infection
Research shows that the combination of daclatasvir and sofosbuvir leads to high rates of sustained virologic response in patients with chronic hepatitis C virus infection, including those who have not responded to previous therapy. (Source: MedWire News - Gastroenterology)
Source: MedWire News - Gastroenterology - January 24, 2014 Category: Gastroenterology Source Type: news

FASEB announces 2014 Science Research Conference: Virus Structure and Assembly
(Federation of American Societies for Experimental Biology) This 2014 FASEB Science Research Conference focuses on structural virology and the application of structure to our understanding of the progression of events that are the virus lifecycle: receptor binding, entry, intracellular trafficking, uncoating, replication, assembly, and exit. Virus assembly includes the process of constructing virions and of marshaling host resources for that purpose. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 22, 2014 Category: Biology Source Type: news

Bacteria-invading virus yields new discoveries
(Florida State University) Innovative work by two Florida State University scientists that shows the structural and DNA breakdown of a bacteria-invading virus is being featured on the cover of the February issue of the journal Virology. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 10, 2014 Category: Biology Source Type: news

Robert Gallo, Co-Discoverer of HIV, Weighs In on "Functional Cures"
When perusing the newswires today, we couldn't help but stop on an interview with Robert Gallo conducted by Dan Rodricks of The Baltimore Sun. Gallo, the virologist who is credited with the co-discovery of the HIV virus alongside Luc Montagner and Françoise Barré-Sinoussi, has always been shrouded in this thin veil of controversy. Not only because of the lingering contentions as to who-really-discovered-what in isolating and identifying the HIV virus, but because he frequently takes the contrarian view as to the direction current research is taking....Read Full Post (Source: About AIDS / HIV)
Source: About AIDS / HIV - January 6, 2014 Category: Consumer Health News Source Type: news

Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
SAN DIEGO, CA--(Healthcare Sales & Marketing Network) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) cleara... Diagnostics, FDAQuidel, AmpliVue, Strep assay, Streptococcus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 30, 2013 Category: Pharmaceuticals Source Type: news

Researchers identify new anti-HIV drug target
University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.Complete findings are printed in today's issue of the Journal of Virology.The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2'-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 27, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

Nigeria: HIV/Aids - Institute Offers Treatment for 28,000 People in 2013
[Leadership]The Institute of Human Virology, Nigeria (IHVN) says that it has placed no fewer than 28,000 persons living with HIV and AIDS on treatment this year. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 27, 2013 Category: African Health Source Type: news

Critics of H5N1 Studies Lobby European Commission
Virologists' letter in support of Ron Fouchier was "misleading," 56 scientists write (Source: ScienceNOW)
Source: ScienceNOW - December 20, 2013 Category: Science Source Type: news

Recent HIV/AIDS News from NIAID, NIH, and FDA
December 18, 2013: Animal Vaccine Study Yields Insights That May Advance HIV Vaccine Research “A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.” Read the NIAID press release.   December 17, 2013: NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks “Principal investigators and clinical trials units (CTUs) have been chosen to lead and conduc...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - December 20, 2013 Category: Infectious Diseases Source Type: news

New anti-HIV drug target identified by University of Minnesota researchers
(University of Minnesota Academic Health Center) University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options. Complete findings are printed in today's issue of the Journal of Virology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2013 Category: Global & Universal Source Type: news

Gilead obtains FDA approval for expanded indication of single tablet HIV-1 regimen Complera
Gilead Sciences has received approval from the US Food and Drug Administration (FDA) for its once-daily single tablet HIV-1 regimen Complera, for use in certain virologically suppressed adult patients on a stable antiretroviral regimen to replace the… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 17, 2013 Category: Pharmaceuticals Source Type: news

Collaborating proteins allow Nipah virus to 'break into' cells
Scientists from Washington State University claim to have discovered how one of the planet's most deadly viruses uses teamwork to "break into" the human cell.Virologist Hector Aguilar-Carreno and his team of researchers were studying how the Paramyxovirus family of viruses, which includes the deadly Nipah virus (NiV), infiltrate cells. The results, published in PLOS Pathogens, reveal that two proteins on the surface of the virus collaborate to gain entry to the cell. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 16, 2013 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

Suppressed but Still InfectiousSuppressed but Still Infectious
HIV RNA can still be detected in the semen of men, despite being on suppressive ART. What are the HIV transmission rates in these patients? Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Identification of emerging threats may be aided by 1950s pandemic bird flu virus
St. Jude Children's Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology.The study included 22 H2N2 avian viruses collected from domestic poultry and wild aquatic birds between 1961 and 2008, making it the most comprehensive analysis yet of avian H2N2 viruses.Researchers reported the viruses could infect human respiratory cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2013 Category: Consumer Health News Tags: Bird Flu / Avian Flu Source Type: news

1950s pandemic influenza virus remains a health threat, particularly to those under 50
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2013 Category: Global & Universal Source Type: news

Study: Antiviral Treatment Effective against CFS; polyDNA Recommends...
A study published on August 19, 2013 in the Journal of Medical Virology found that valganciclovir (VGCV) “may have clinical benefit in a subset of CFS patients (1).” polyDNA reviews the literature on...(PRWeb November 27, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11366523.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 28, 2013 Category: Pharmaceuticals Source Type: news

HCV Viral Load at Baseline Sets Need for Protease Inhibitors (CME/CE)
(MedPage Today) -- Hepatitis C genotype I patients with low viral load and sustained virologic response may be able to cut protease inhibitors from therapy, researchers found. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 27, 2013 Category: Gastroenterology Source Type: news

One Health: The Human-Animal-Environment Interfaces in Emerging Infectious Diseases
Food Safety and Security, and International and National Plans for Implementation of One Health Activitiesseries:Current Topics in Microbiology and ImmunologyThe second volume on One Health explains in detail how to implement three key aspects of the One Health paradigm—food safety and security, national plans for a holistic one health approach, and relevant new technologies and approaches. The fourteen chapters, each by an internationally recognized authority, are organized into three sections of four or five chapters each, that break new ground ... (Source: Springer Biomedical Sciences titles)
Source: Springer Biomedical Sciences titles - November 24, 2013 Category: Biomedical Science Tags: Virology Source Type: news

On This Day in Science History - November 17 - Hans Zinsser
November 17th is Hans Zinsser's birthday. Zinsser was an American virologist who built his career on the typhus fever. He traveled the world with the Red Cross investigating outbreaks of ...Read Full Post (Source: About.com Chemistry)
Source: About.com Chemistry - November 16, 2013 Category: Chemistry Source Type: news

Dr. Robert Gallo named first Homer & Martha Gudelsky Distinguished Professor in Medicine
(University of Maryland Medical Center) Robert C. Gallo, M.D., has been named the first Homer & Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine during a ceremony November 7. The ceremony also honored the Gudelsky Family Foundation for their extraordinary generosity in supporting the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, MD. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 12, 2013 Category: Global & Universal Source Type: news

Vaccine fraud exposed: Measles and mumps making a huge comeback because vaccines are designed to fail, say Merck virologists
Disclaimer: I am not an opponent of the theory of inoculation. Nor am I opposed to science. What I am opposed to is fraudulent science, and that's what this article is all about. Measles and mumps are making a huge comeback in the United States, but doctors and journalists... (Source: NaturalNews.com)
Source: NaturalNews.com - November 11, 2013 Category: Consumer Health News Source Type: news

HCV Regimen: No Interferon, No Ribavirin, No Problem (CME/CE)
WASHINGTON (MedPage Today) -- Patients who failed to respond to standard treatment for hepatitis C virus infection achieved greater than 80% sustained virologic response with a regimen that eschewed both interferon and ribavirin, researchers reported. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 8, 2013 Category: Gastroenterology Source Type: news

All-Oral Treatment Suppresses Hep C in HIV Patients (CME/CE)
WASHINGTON (MedPage Today) -- An all-oral regimen to treat hepatitis C in patients co-infected with HIV achieved a sustained virologic response against the hepatitis virus without disrupting suppression of the HIV, researchers said here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - November 7, 2013 Category: Consumer Health News Source Type: news

3-Drug Combo Halts HCV Infection
WASHINGTON (MedPage Today) -- An investigational three-drug oral combination that avoids the use of both interferon and ribavirin allows a high percentage of patients infected with hepatitis C virus to achieve a sustained virologic response, researchers said here. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 7, 2013 Category: Gastroenterology Source Type: news

Dyslipidemia, Atherosclerosis and CV Disease in HIV PatientsDyslipidemia, Atherosclerosis and CV Disease in HIV Patients
As the population living with HIV ages, understanding cardiovascular disease in the setting of HIV is of increasing importance. Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

New antivirals eradicate hepatitis C in trial
Sofosbuvir and ledipasvir stop virus replicating in 97% of patients in study reported in the Lancet journalScientists have reported the successful eradication of hepatitis C in patients using two new antiviral drugs, raising hopes of a possible cure.In the trial, the virus was eliminated from almost all the patients involved, including those who had not previously responded to existing drugs.Hepatitis C is caused by a virus that spreads via bodily fluids and ends up damaging the liver. Unlike other forms of hepatitis, there is no vaccine and the only treatments include powerful combinations of drugs known as interferons an...
Source: Guardian Unlimited Science - November 5, 2013 Category: Science Authors: Alok Jha Tags: theguardian.com United States News Health Medical research Society Drugs Hepatitis C Cancer UK news Science Source Type: news

HCV Yields to Combo, While HIV Stays Suppressed
WASHINGTON (MedPage Today) -- Combination therapy to treat patients co-infected with HIV and hepatitis C virus (HCV) achieved a high percentage of virologic response to the hepatitis infection without affecting suppression of the HIV, researchers reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 5, 2013 Category: Primary Care Source Type: news

Tanzania becomes battleground for GM crops | Sharon Schmickle
This article appeared in Guardian Weekly, which incorporates material from the Washington PostTanzaniaAfricaGMFarmingSustainable developmentEnvironmental sustainabilityFood securityUnited StatesEuropeSharon Schmickletheguardian.com © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 5, 2013 Category: Science Authors: Sharon Schmickle Tags: United States Farming Food security World news Europe GM Environmental sustainability Editorial Guardian Weekly Sustainable development Global development Tanzania Africa Science Source Type: news

Phase 3 results announced for an all oral, sofosbuvir-based regimen for the treatment of hepatitis C in patients co-infected with HIV
Gilead Sciences, Inc. (Nasdaq: GILD) has announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue inhibitor sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients co-infected with HIV. In the trial, 76 percent (n=87/114) of genotype 1 HCV treatment-naïve patients receiving 24 weeks of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin (RBV) achieved a sustained virologic response 12 weeks after completing therapy (SVR12). Patients who achieve SVR12 are considered cured of HCV infection... (Source: Health New...
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Dateline City: WHITEHOUSE STATION, N.J. Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C vir...
Source: Merck.com - Research and Development News - November 2, 2013 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Racial Differences in Response to Antiretroviral Therapy
A recent study sought to separate psychosocial influences from biological factors at work in the higher rates of virologic failure among black Americans vs whites. (Source: Consultant Live)
Source: Consultant Live - November 1, 2013 Category: Primary Care Source Type: news

Addressing the Public Health Burden of Respiratory VirusesAddressing the Public Health Burden of Respiratory Viruses
The Battle against Respiratory Viruses (BRaVe) Initiative is taking a stand against respiratory infections. Here's how. Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2013 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Biosecurity, sanitation important for prevention of deadly emerging pig virus in the United States
Veterinary researchers at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech have helped identify the origin and possible evolution of an emerging swine virus with high mortality rates that has already spread to at least 17 states. A team of researchers led by Dr. X.J. Meng, University Distinguished Professor of Molecular Virology, has used virus strains isolated from the ongoing outbreaks in Minnesota and Iowa to trace the likely origin of the emergent porcine epidemic diarrhea virus (PEDV) to a strain from the Anhui province in China... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 24, 2013 Category: Consumer Health News Tags: Veterinary Source Type: news

UCLA gets $7M to study substance use and HIV among minority men who have sex with men
The National Institute on Drug Abuse has awarded UCLA a $7 million grant to investigate the links between substance abuse and HIV among Latino and African-American men who have sex with men.   Researchers will examine how non-injected drugs and alcohol can directly interact with the virus and other infectious diseases, to damage these men's health. Enrollment in the study begins in January.   Called MASCULINE (MSM and Substances Cohort at UCLA Linking Infections Noting Effects), the study will be led by Pamina Gorbach, a professor of epidemiology at UCLA's Fielding School of Public Health and a professor of inf...
Source: UCLA Newsroom: Health Sciences - October 21, 2013 Category: Universities & Medical Training Source Type: news

New and more virulent strain of HIV is spreading rapidly through Russia, claim scientists
Researchers at the State Research Center of Virology and Biotechnology VECTOR in Siberia say 02_AG/A accounts for half of new HIV infections in the area. (Source: the Mail online | Health)
Source: the Mail online | Health - October 17, 2013 Category: Consumer Health News Source Type: news

Danoprevir Combo Cuts Hep C Viral Load (CME/CE)
(MedPage Today) -- The addition of danoprevir to peginterferon and ribavirin therapy for hepatitis C increased patients' sustained virologic response, researchers found. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 16, 2013 Category: Gastroenterology Source Type: news

Effect of HCV in HIV-Infected Patients Initiating HAARTEffect of HCV in HIV-Infected Patients Initiating HAART
How does HCV affect the immunological and virological responses in HIV-infected patients starting HAART? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Origin of MERS coronavirus identified
The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) has circulated in bats for a substantial time, before making the species leap to humans, according to research published in BioMed Central's open access publication Virology Journal. By analysing the genome of various bat species, scientists show that bat DPP4 genes have adapted significantly as they evolved, suggesting a long-term arms race between the bat and the virus... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 11, 2013 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

HPV and HIV CoinfectionHPV and HIV Coinfection
HIV/HPV is more than a simple coinfection. Each display interactions favoring the other infection at the cellular level. Future Virology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 10, 2013 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

New insights into how JC polyomavirus invades cells
For more than a decade the research group of Brown University Professor Walter Atwood has doggedly pursued the workings of the JC polyomavirus, which causes a disease called PML that fatally degrades the central nervous system of patients with weakened immune systems. In a study published online in the Journal of Virology, his team describes how it gains entry into cells: It breaks in via certain receptors of the neurotransmitter serotonin called 5-HT2 receptors... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 9, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

HBV mutations double following vaccination campaign
A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies. Researchers at the Chinese Centers for Disease Control and Prevention and University of North Carolina, Chapel Hill, report their findings in an article published ahead of print in the Journal of Virology. Until a universal vaccination program for infants was implemented in 1992, nearly ten percent of Chinese - children included - were infected with HBV... (Source: Health News ...
Source: Health News from Medical News Today - October 9, 2013 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

Virology, Natural History, and Treatment for HCV Genotype 3Virology, Natural History, and Treatment for HCV Genotype 3
Read this new study to learn about advancements in understanding and treating HCV genotype 3. Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Making the most of what you have
(University of Veterinary Medicine -- Vienna) Understanding how viral proteins are produced can provide important clues on how we might interfere with the process. The group of Till Rümenapf at the University of Veterinary Medicine Vienna has discovered that a key protease of a particular virus breaks itself down into two different functional molecules. The findings are reported in the Journal of Virology and may have important implications for the development of defense strategies against diseases caused by flaviviruses. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2013 Category: Global & Universal Source Type: news

Viral Load Monitoring and Outcomes in HAART PatientsViral Load Monitoring and Outcomes in HAART Patients
Do patients with negative PCR results have better virological outcomes than those with PVL (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 7, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Vaccination campaign doubles HBV mutations
(American Society for Microbiology) A universal infant vaccination campaign in China has led the hepatitis B virus to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies. Researchers at the Chinese Centers for Disease Control and Prevention and University of North Carolina, Chapel Hill, report their findings in an article published ahead of print in the Journal of Virology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2013 Category: Global & Universal Source Type: news

How JC Polyomavirus invades cells
(Brown University) A new study in the Journal of Virology identifies the means by which the JC Polyomavirus enters host cells. It's a particular subset of serotonin receptors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2013 Category: Global & Universal Source Type: news